![]() |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
|
Lista de Categorias
AlcoolismoAlzheimer E ParkinsonAnalgésicosAnti-InflamatóriosAnti-helmínticosAnti-viraisAntialérgicosAntibióticosAnticoncepcionaisAnticonvulsivantesAntidepressivosAntifúngicosArtriteAsmaCancroCirúrgiaColesterolCuidados Da PeleCuidados Para Los OjosDiabetesDisfunção EréctilDiuréticosDoenças CardiovascularesEnxaquecasH I VHipertensão ArterialObesidadeOsteoporosePerturbações MentaisPerturbações NeurológicasRelaxantes MuscularesSaúde FemininaSaúde MasculinaTrato GastrointestinalTrato RespiratórioTrato Urinário 17 May 2012 06:52:05
טבע: יעדי 2015 אופטימיים מדי? : 2015 ? ר ר ר Lexapro, Avapro Avalide ר ר , , ר . ר ר Lexapro ר ר 2.5 ר ר, ...14 May 2012 10:02:22
Teva Pharmaceuticals' Disappointing ResultsTeva Pharmaceuticals' Disappointing Results Seeking Alpha The company recently announced that it has started selling Irbesartan and irbesarten-hydrochlorothiazide tablets, a generic version of Sanofi-Aventis' high blood pressure drugs, Avapro and Avalide tablets. Teva also has exclusivity to market the ...
07 May 2012 04:33:53
Top global pharma cos post sales growth of just 3.4%, but net profit up by ...Top global pharma cos post sales growth of just 3.4%, but net profit up by ... pharmabiz.com Similarly, Aciphex Pariet of J&J , NeoRecormon Epogin of Roche and Avapro Avalide of Bristol-Myers lost blockbuster status in 2011. Besides, Lipitor and Seretide Advair, few important blockbuster products like MabThera Rituxan (Roche), ...
05 May 2012 00:19:38
Earnings Scorecard: Bristol-Myers - Analyst BlogEarnings Scorecard: Bristol-Myers - Analyst Blog NASDAQ Revenues were just shy of the Zacks Consensus Estimate of $5.26 billion, mainly due to lower sales of Plavix and Avapro Avalide . US net sales in the quarter climbed 6% to $3.5 billion. Sales in international markets increased 2% to $1.8 billion.
30 Apr 2012 15:52:22
Sanofi Beats on EPS, View BackedSanofi Beats on EPS, View Backed Zacks.com Aprovel Avapro Karvea Avalide revenues declined 18.1% to 404 million due to increased generic competition. The product lost its exclusivity on March 30, 2012. Lovenox, Ambien CR and Taxotere, performed disappointingly due to generic competition in the ...
|
|
Choose Your language:
Pesquisa no site:
Testemunhos
Olá, obrigado,
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Mais vendidos|Política|Questões Mais Frequentes|Testemunhos|Contacte-nos|Sitemap |
|
|
|
|
| |